Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Evaluation of Masticatory Performance in Patients With Periodontitis

NCT07665489 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2026-09-01
Last updated
2026-07-06

Condition(s) studied

Periodontitis, AdultPeriodontitisOral Disease

Study summary

The objective of this observational study is to assess the correlation between the severity of periodontal involvement and masticatory performance in patients with periodontitis.

The secondary objectives are to identify periodontal parameters that may be associated with a reduction in masticatory performance.

This study includes a single group.

Participants will be asked to perform a masticatory performance test consisting of chewing a piece of gum for 20 cycles.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients followed at the university hospital (CHU) with a diagnosis of periodontitis. * No objection from the patient to participate in the study. * Patients able to speak and understand French. Exclusion Criteria: * Minors. * Patients under legal protection (guardianship, trusteeship, or judicial protection measures). * Pregnant or breastfeeding women. * Patients who refuse to participate in the study.

Primary outcome measure(s)

  • Value of the patient's masticatory performance — Baseline
    Value of the patient's masticatory performance, obtained from the masticatory performance test (two-color chewing gum test) (quantitative variable).

Trial sites (1)

FacilityCityRegionStatus
CHU Clermont-Ferrand Clermont-Ferrand France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07665489 on ClinicalTrials.gov ↗ ← All trials in France